Pulse Biosciences, Inc. provided revenue guidance for the fourth quarter 2021. Preliminary unaudited full year 2021 revenue is expected to be in the range of $1.3 million to $1.4 million, including preliminary unaudited fourth quarter 2021 revenue of approximately $750,000.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
12.86 USD | +13.10% | +31.76% | +4.74% |
05-20 | Pulse Biosciences Moves New Record Date for Rights Offering | MT |
05-14 | Pulse Biosciences Appoints Burke Barrett as President, CEO | MT |
1st Jan change | Capi. | |
---|---|---|
+4.74% | 628M | |
+7.57% | 223B | |
+11.51% | 195B | |
+18.91% | 144B | |
+30.07% | 111B | |
+2.32% | 65.19B | |
+14.11% | 53.02B | |
+2.68% | 50.28B | |
+6.25% | 44.15B | |
+1.69% | 36.45B |
- Stock Market
- Equities
- PLSE Stock
- News Pulse Biosciences, Inc.
- Pulse Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter 2021